As interim co-lead counsel, we represent a proposed class of end payors who allege that Teva—one of the largest pharmaceutical manufacturers in the world—engaged in an anticompetitive scheme to shield its multiple-sclerosis drug, Copaxone, from generic competition (e.g., by pressuring PBMs to exclude generic Copaxone from their formularies). The case is in the discovery phase of litigation.